Following our data analysis coupled to pathway and linkage disequilibrium analyses, we show that selected VEGFA genomic variants are associated with β-thalassemia disease severity and HU treatment efficacy in SCD/β-thalassemia compound heterozygous patients, suggesting that VEGFA may be considered as a modifier gene for HbF production. Here, VEGFA is linked to Schnyder corneal dystrophy.